Effect of a cholinomimetric drug (RS 86) in tardive dyskinesia and drug-related parkinsonism

U. Noring, U. Juul Povlsen, Daniel Casey, J. Gerlach

Research output: Contribution to journalArticle

32 Scopus citations


RS 86, a specific muscarinic agonist, was evaluated in a blind, placebo-controlled, single-dose trial in 10 psychiatric patients with stable tardive dyskinesia (TD). RS 86, 0.5-4 mg orally, produced no significant effects in TD, although 4 mg caused a minimal aggravation in parkinsonism. Side effects of the highest dose (4 mg) included hypersalivation (eight patients), nausea (6), sweating (3), and vomiting (3). It is concluded that treatmetn with RS 86 and probably other cholinomimetics has no or only limited beneficial effect in TD.

Original languageEnglish (US)
Pages (from-to)569-571
Number of pages3
Issue number4
Publication statusPublished - Dec 1984



  • Cholinomimetics
  • Parkinsonism
  • RS 86
  • Tardive dyskinesia

ASJC Scopus subject areas

  • Pharmacology

Cite this